logo
'A beautiful partnership': Children take part in 'Summer at Sem, Explorations with the Y' program

'A beautiful partnership': Children take part in 'Summer at Sem, Explorations with the Y' program

Yahoo5 hours ago

Jun. 21—Which solution was the best for making lots of big bubbles?
Turning to the 6- to 9-year-olds in her classroom, Wyoming Seminary science teacher asked them to remember their previous experiments.
Did the store-bought solution work best?
"No!"
What about the homemade solution with sugar?
"No!"
Could it have been the homemade solution with glycerin?
"Yes!" came the answer from a dozen budding scientists, who eagerly blew huge streams of bubble using their best solution and bubble blowers that had been handcrafted from plastic bottles with the bottoms cut off and replaced by a cloth that was held in place by a rubber band.
The kids vied to make the tallest towers of bubbles, and some of them used their hands to sculpt bubbles into interesting shapes. It was all part of the fun at Summer at Sem, Explorations with the Y, a 3-week program that attracted 113 campers to Wyoming Seminary's Lower School campus in Forty Fort for sessions as diverse as LEGO robotics, photography, basketball and waterplay.
"We have everything here," Cheryl Connolly, Wyoming Seminary director of advancement, said Friday, as children took part in the final day of camping activities.
"It's a beautiful partnership," Sara Hargadon Michaels, camp director, said of this year's cooperative effort between Wyoming Seminary and the Y, which welcomed students from other schools to join Wyoming Seminary's program, which dates back to the 1990s.
Michaels said she had seen children blossom at the camp. "You see the timidness of their first arrival turn into vibrancy and confidence as they soak up the energy of the camp."
In one classroom, children sang about waddling ducks approaching a lemonade stand as they rehearsed a skit. In another, Wilkes-Barre Area kindergarten teacher Maria Hayward helped them use up some of their physical energy playing with balloons before they headed outdoors to draw with chalk. And in a gym, dozens of campers were dribbling basketballs.
With faculty members from Wyoming Seminary and program specialists from the YMCA facilitating, Michaels said, "what has been provided has only enhanced what has traditionally been presented in the past. Favorites such as LEGO Stop Motion, Chemistry, Magic School Bus, Ocean Explorations, Cardboard Creations and Chef for a Day were joined by Pickleball, Speed and Agility and Sports from Around the World."
While those camps were targeted at first through eighth graders, toddlers stayed busy with waterworks, sensory play and more with their teacher Margaret McCann in Arlington House, a separate building on the campus.
"The partnership has been a fantastic experience, one that we hope to build on moving forward," Michaels said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes
Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Yahoo

time15 minutes ago

  • Yahoo

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and disease progression in patients. An analysis of the STRIDE trial was presented as a late-breaking symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in Diabetes Care®. PAD is a serious condition impacting 230 million individuals globally and up to 30% of people with diabetes. PAD narrows arteries and reduces blood flow to the legs, causing marked disability, affecting quality of life, and putting people at increased risk of severe complications including amputations and death. Treatment options are currently limited, and little advancements in PAD treatment have occurred for more than 25 years. The STRIDE trial is a phase 3, multinational, double-blind, randomized clinical trial conducted at 112 outpatient clinical trial sites in 20 countries in North America, Asia, and Europe. 792 patients aged 18 years and older with type 2 diabetes and PAD with intermittent claudication (a symptom of PAD that causes muscle pain or cramping in the legs during physical activity) and reduced ankle-brachial or toe-brachial index (indicators of restricted blood flow to the legs), were randomly assigned to receive either semaglutide (n=396) or placebo (n=396) over a 52-week period to assess the impact on walking capacity, symptoms, and quality of life. The median age was 68 years, and 195 (25%) participants were female and 597 (75%) were male. The sub-analysis builds on results previously published in The Lancet, demonstrating that semaglutide significantly improved walking outcomes in people with PAD and diabetes, enhanced quality of life, and reduced the risk of disease progression by 54%. At week 52, the estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group. Semaglutide was well tolerated, with no treatment-related deaths and a low rate of serious adverse events (1%), consistent with its known safety profile. The analyses from STRIDE presented new and critical information on the benefits of semaglutide, which were observed independent of baseline levels of A1C, duration of diabetes, or intensity of diabetes. Furthermore, the benefits were seen across all BMI categories and regardless of the treatment with SGLT2 inhibitors. "These findings indicate that clinicians can now recognize semaglutide as a vascular protective medication, with benefits that extend beyond lowering weight or A1C," said Professor Subodh Verma, MD, PhD, FRCSC, FAHA, FCAHS, cardiovascular surgeon, University of Toronto, Toronto, Canada, and senior author of the STRIDE trial. "The totality of data now suggest that in people with diabetes, semaglutide favorably affects the pipes [atherosclerosis], pump [heart failure], filter [kidney outcomes]. And, in patients with PAD, these new data provide robust evidence that semaglutide is a therapy to improve their function, quality of life, and progression of disease."The study authors indicate that further research is warranted to understand whether these benefits extend to individuals with PAD who do not have diabetes. Research presentation details:Dr. Verma will present the findings at the following symposium: Symposium: Diabetes and Peripheral Artery Disease—Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial Presented on Saturday, June 21 at 1:30 p.m. CT About the ADA's Scientific SessionsThe ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Media Contact: Mimi Carmody, MCarmody@ View original content to download multimedia: SOURCE American Diabetes Association Sign in to access your portfolio

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Associated Press

time24 minutes ago

  • Associated Press

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20–23, 2025, in Chicago, Illinois. 'Our preclinical data demonstrated that APJ activation can confer multiple benefits in models of diabetic obesity and heart failure, and enhance the effects of incretin therapy,' said Kristen Fortney, PhD, CEO and co‑founder of BioAge. 'We are advancing next‑generation APJ agonists to translate this promising biology into new therapies for obesity and its major comorbidities.' APJ is the receptor for apelin, an exercise-induced signaling molecule known as an exerkine. Apelin has been shown in preclinical studies to have the potential to recapitulate many of the downstream benefits of exercise. BioAge's discovery platform identified apelin signaling as a therapeutic target based on analysis of human aging cohorts, which revealed that higher levels of circulating apelin are predictive of improved physical function and increased longevity. BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring body composition and muscle function, suggesting that APJ agonists could serve as pharmacological exercise mimetics to enhance incretin therapy. BioAge is advancing multiple APJ agonist approaches, including both oral small-molecule and long-acting injectable formulations, with an IND filing targeted for 2026 [ link ]. In their two presentations, BioAge CMO and EVP Research Paul Rubin, MD, and scientist Shijun Yan, PhD, MBA, will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. Oral presentation: Saturday Jun 21, 2025 5:00 PM - 5:15 PM CDT Title: An Oral Apelin Receptor Agonist Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide Session: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies—Take 1; W181 A-C Presenter: Paul Rubin, MD, Chief Medical Officer and EVP-Research Poster presentation: Sunday Jun 22, 2025 12:30 PM - 1:30 PM CDT Title: The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection Fraction Session: Poster Hall F1, Board No. 866 Presenter: Shijun Yan, PhD, MBA, Senior Scientist, In Vivo Biology The visual materials for the presentations will be made available on the BioAge investor website concurrent with the beginning of their respective sessions. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. IND submission and initiation of a Phase 1 SAD/MAD trial are planned for mid-2025, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging. Forward-looking statements This press release contains 'forward-looking statements' within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, including BGE-102 and our APJ program, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of our IND filing for BGE-102 or our APJ program, our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates or their ultimate ability to treat human disease, the expected timeline for completing proteomic analysis, anticipated analytical results and the potential for identifying novel therapeutic targets, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'possible,' 'will,' 'would,' and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading 'Risk Factors' included in BioAge's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 6, 2025, and BioAge's other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Contacts PR: Chris Patil, [email protected] IR: Dov Goldstein, [email protected] Partnering: [email protected] Web:

The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care
The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care

Associated Press

time24 minutes ago

  • Associated Press

The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care

This challenge Kickstarts additional investments through the new ADA Innovation Fund CHICAGO, June 21, 2025 /PRNewswire/ -- As the American Diabetes Association® (ADA) celebrates its 85th anniversary, it continues to fuel transformative progress in the fight to end diabetes—and increasingly, obesity. This year's Innovation Challenge, held during the ADA's 85th Scientific Sessions, highlighted bold ideas driving the future of diabetes treatment and support. Five visionary finalists presented their innovations on the main stage before a panel of expert judges and a live audience. Three outstanding winners were selected for their potential to revolutionize diabetes care: Kihealth, MYNERVA, and Kayothera, INC. 'One of the biggest things we've learned in our 85 years is that in the fight to end diabetes, every new bit of knowledge, every advancement in treatment, every novel idea matters. We're proud to support these innovators as they help shape a future free of diabetes and all its burdens,' said Elle Uh, the ADA's chief strategy officer and chief of staff. This year's winners and finalists included: Winner: Kihealth—A diagnostic test to measure the rate of beta cell death through a liquid biopsy, providing patients and clinicians with a clear view of metabolic health and an earlier window into disease development. Winner: MYNERVA—An AI-driven neuroprosthetic smart sock for diabetes-related neuropathy to reduce pain and regain stability. Winner: Kayothera, INC—A first-in-class antagonist of the undruggable retinoid pathway to treat and potentially reverse type 2 diabetes. Finalist: BioDynamik, Inc.—An orthopedic-driven angiogenesis to restore perfusion for the healing of recalcitrant ischemic ulcers. Finalist: Generated Health—A chatbot combining AI-driven automation and human-like empathy with a simple text-based platform designed to support both patients and health care teams. The Innovation Challenge occurs at a critical time. Over 38 million Americans live with diabetes and about 125 million live with obesity. To meet these interconnected epidemics head-on, the ADA is launching the ADA Innovation Fund, a venture philanthropy fund designed to advance the ADA's mission by investing in innovative, high-impact companies developing diabetes, obesity, and other comorbidity-related solutions. Leveraging the ADA's 85-year history of funding hundreds of millions of dollars in innovative research grants, these investments aim to continue to accelerate mission-critical scientific breakthroughs, reduce health disparities, and promote sustainable health care solutions. About the ADA's Scientific Sessions The ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook ( American Diabetes Association ), Spanish Facebook ( Asociación Americana de la Diabetes ), LinkedIn ( American Diabetes Association ), and Instagram ( @AmDiabetesAssn ). To learn more about how we are advocating for everyone affected by diabetes, visit us on X ( @AmDiabetesAssn ). View original content to download multimedia: SOURCE American Diabetes Association

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store